ERBB2 and breast cancer: Intravenous injection of NK‐92‐scFv(FRP5)‐zeta cells expressing a CAR specific to the tumour‐associated (HER2/neu) antigen into the tail vein of mice bearing HER2/neu‐positive NIH 3 T3 breast cancers was shown to reduce progressive signals in HER2/neu‐positive breast cancers 12 and 24 hours after injection.192